NCT04624256 - Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial | Biotech Hunter

Enrollment

226

Participants

Timeline

Start Date

November 10, 2020

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions

Prostate AdenocarcinomaStage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8Stage II Prostate Cancer AJCC v8Stage IIA Prostate Cancer AJCC v8Stage IIB Prostate Cancer AJCC v8Stage IIC Prostate Cancer AJCC v8

Interventions

PROCEDURE

Discussion

Patients and physicians engage in discussion

RADIATION

Hypofractionated Radiation Therapy

Undergo conventional hypofractionated radiation therapy

RADIATION

Hypofractionated Radiation Therapy

Undergo moderate hypofractionated radiation therapy

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

RADIATION

Stereotactic Body Radiation Therapy

Undergo SBRT

Trial Locations (1)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles